November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
November 2023 in “Scientific reports” The research identified and described a gene important for hormone conversion in endangered catfish, which varies in activity during different reproductive stages and after hormone treatment.
June 2023 in “International journal of pharmaceutical quality assurance” Eclipta alba extract could be a promising natural treatment for hair loss.
February 2021 in “International Journal of Science and Research (IJSR)” A higher testosterone/dihydrotestosterone ratio in PCOS patients may indicate worse metabolic health.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
Teak leaf extract can help treat hair loss, and its effectiveness varies by geographic origin.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
February 2025 in “Iranian journal of pharmaceutical research”
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
July 2024 in “Behavioural Brain Research” Long-term finasteride treatment reduces depression and brain issues in obese male rats.
June 2024 in “Ecotoxicology and Environmental Safety” Finasteride harms Daphnia magna's reproduction, growth, and metabolism.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.